Intraventricular haemorrhage (IVH) is a critical complication in preterm infants, predominantly affecting those born before 30 weeks of gestation or weighing less than 1500 grams. Although improvements in perinatal and neonatal care have increased the survival rate of preterm infants, particularly those born at a gestational age of less than 25 weeks1, IVH continues to be a significant source of morbidity and mortality. The incidence of IVH in such infants remains approximately 25–30%2,3. These findings highlight the challenge of determining optimal management strategies for IVH. This review provides an overview of IVH pathophysiology, risk factors, and management, emphasising evidence-based approaches across antenatal, perinatal, and postnatal care.
IVH primarily originates in the germinal matrix, a transient, highly metabolically active, and highly perfused cell layer along the lateral ventricles. This layer is responsible for the precursors of cortical neurons and hemispheric glial cells, which subsequently migrate peripherally in a programmed pattern. The germinal matrix is most active during early gestation and progressively involutes, with only a small residual component remaining at the caudothalamic groove by 32–34 weeks of gestation4. The high vascularity of the germinal matrix makes it particularly vulnerable to haemorrhage, especially in preterm infants, where its immature vasculature—characterised by thin-walled capillaries—is prone to rupture under stress. Contributing factors to this vulnerability include:
Prenatal Risk Factors:
Postnatal Risk Factors:
Ultrasonography: Cranial ultrasonography is the gold standard for IVH diagnosis, allowing early detection of bleeding and monitoring for complications like post-haemorrhagic ventricular dilatation (PHVD).
Papile Grading System8:
MRI for Prognosis: While cranial ultrasonography remains the gold standard for routine monitoring and early detection of IVH, it has limitations, particularly in detecting minor injuries to the cerebellum and grey and white matter. Magnetic resonance imaging (MRI) is considered superior for visualizing white matter injury and providing a more comprehensive assessment of brain damage. However, MRI poses several challenges for widespread use in preterm infants. It is difficult to perform in the early period because most neonates are unstable for transportation, the imaging process is time-consuming, anaesthesia is required, and it is an expensive procedure. Additionally, it may not alter management in the early stages. Despite these challenges, studies have shown that MRI, particularly for assessing white matter injury, is more effective when performed after the postconceptional age of 40 weeks. At this stage, MRI can offer valuable insights into both short- and long-term neurodevelopmental outcomes.
Antenatal Management:
Perinatal Management:
Postnatal Management:
Optimising the care of preterm infants during the critical first 72 hours of life has been extensively studied as a strategy to reduce the incidence of IVH. However, results across studies remain inconsistent, highlighting the need for further research to establish optimal management protocols. Commonly accepted practices include18,19,20,21.
IVH can lead to serious complications, including periventricular haemorrhagic infarction (PVHI), post-haemorrhagic ventricular dilation (PHVD), periventricular leukomalacia, and cerebellar haemorrhage.
PVHI typically occurs unilaterally, causing injury to corticothalamic pathways and disrupting neuronal and glial migration. This negatively impacts gray matter development. PVHI is associated with significant long-term complications: cerebral palsy in 60% of cases, cognitive impairments in 50%, visual field defects in 25%, and epilepsy in 20%. Mortality risk increases with the severity of the injury22,23.
PHVD often develops 1–3 weeks after severe IVH, affecting approximately one-third of very-low-birth-weight preterm infants. Progressive hydrocephalus occurs in about half of these cases, with surgical intervention required in roughly 15%. Early detection is critical, and regular monitoring of head circumference is essential. An increase of more than 1 mm per day warrants further investigation to diagnose and manage PHVD effectively22.
Currently, there is no definitive treatment for IVH. Management focuses on supportive care, including stabilising hemodynamic, ensuring adequate oxygenation and ventilation, providing appropriate fluid and nutritional support, controlling seizures, and addressing complications as they arise.
The prognosis for IVH depends on the severity of haemorrhage, the presence of parenchymal injury, and the occurrence of seizures or the need for shunt placement8,24. Infants with grade I-II IVH may experience neurodevelopmental delay, hearing loss, and cerebral palsy. In grade I IVH, cerebral palsy occurs in 6.8% of cases, and in grade II IVH, in 8.1%25. The incidence of cerebral palsy increases in the presence of ventricular dilatation or cystic periventricular leukomalacia. In grade III-IV IVH, cerebral palsy occurs in over 50% of cases, with 75% of children requiring special education. The incidence of severe neurodevelopmental disorders in grade IV IVH may exceed 55%, rising to 86% when PVHI and shunting are present22.
According to NICE guideline (NG72), comprehensive neurodevelopmental follow-up, including physical therapy, occupational therapy, and specialised educational support, is essential to optimize outcomes for affected infants.
Preventing and managing IVH in preterm infants requires an integrative approach spanning antenatal, perinatal, and postnatal care. Evidence-based strategies such as antenatal corticosteroids, delayed cord clamping, optimised ventilation, and neuroprotective bundles have proven effective in reducing IVH incidence and severity. Continued research into innovative therapies and long-term support systems is crucial to improving outcomes for this vulnerable population.
Neonatal Consultant, Bradford Royal Infirmary
THERAPIES
Armstrong Medical Ltd is a limited company registered in Northern Ireland
Wattstown Business Park, Newbridge Road, Coleraine, Co. Derry/Londonderry, BT52 1BS, United Kingdom
VAT Number: GB432578934
Company Number: NI025560